Interest in Use of Fewer Radiation Treatments Across Cancer Types is Accelerating, Says Expert


Data presented at a recent medical conference shows that there is continued interest in observing the effects of fewer radiation treatments across several cancer types, according to an expert.

The use of hypofractionated radiation—fewer radiation treatments at larger doses—in several cancer types is accelerating, according to an expert.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, CancerNetwork® spoke with Louis Potters, MD, FACR, FABS, FASTRO, about some of the potentially practice-changing results in the radiation oncology space that were presented at the conference.

Potters, who is the chair of the Department of Radiation Medicine and deputy physician-in-chief of Northwell Health Cancer Institute in New Hyde Park, New York, said that the accelerated use of hypofractionated radiation, especially in the prostate and breast cancer settings, as well as using radiation to manage oligometastatic disease were some key overarching themes of the data seen at ASTRO.


I really did enjoy the meeting a lot this year; there was a lot of really good science. Not only that, it was really nice seeing colleagues and friends after not having seen them for the last number of years. If one was to take away an overall theme from the meeting, it was the continued acceleration of hypofractionation: the idea of using fewer treatments for any disease in particular. There was a lot of data on breast and prostate [cancer]. Secondly, an overarching macro-theme was the opportunity to use radiation for oligometastatic disease. There was discussion about prostate cancer in particular [and] other diseases as well in either a curative approach or in a palliative type of setting.

Related Videos
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.